Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 4/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 1.00 |
| ▸ | IGF1R | P08069 | 2/20 | 1.00 |
| ▸ | CTRC | Q99895 | 1/20 | 0.67 |
| ▸ | RAF1 | P04049 | 1/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.65 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.65 |
| ▸ | DHFR | P00374 | 1/20 | 0.65 |
| ▸ | PLK4 | O00444 | 3/20 | 0.60 |
| ▸ | PLK1 | P53350 | 3/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | EEF2K | O00418 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5472251 | 1.00 | ERBB2 (1.00) | ERBB2EGFRIGF1RCTRCRAF1 | |
| SCHEMBL7312530 | 0.85 | ERBB2 (0.73) | ERBB2EGFRIGF1RCTRCRAF1 | |
| SCHEMBL7312535 | 0.85 | ERBB2 (0.73) | ERBB2EGFRIGF1RCTRCRAF1 | |
| SCHEMBL7319104 | 0.85 | ERBB2 (0.73) | ERBB2EGFRIGF1RCTRCRAF1 | |
| SCHEMBL7319107 | 0.85 | ERBB2 (0.73) | ERBB2EGFRIGF1RCTRCRAF1 | |
| SCHEMBL5468784 | 0.84 | LRRK2 (0.72) | ERBB2EGFRIGF1RCTRCPDGFRB | |
| SCHEMBL5468785 | 0.84 | LRRK2 (0.72) | ERBB2EGFRIGF1RCTRCPDGFRB | |
| SCHEMBL6694978 | 0.84 | ERBB2 (0.72) | ERBB2EGFRIGF1RCTRCRAF1 | |
| SCHEMBL6688476 | 0.84 | ERBB2 (0.72) | ERBB2EGFRIGF1RCTRCRAF1 | |
| SCHEMBL5083132 | 0.82 | RAF1 (0.71) | ERBB2EGFRIGF1RCTRCRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
| WO-2004069998-A2 | OXINDOLE DERIVATIVES AS ANTIMICROBIAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2004-08-19 | — | — | WO | disclosed |
| US-6420428-B1 | TREATING HEPATITIS C AND HEPATIC FIBROSIS USING 2,6-DI-TERT-BUTYLPHENOL DERIVATIVES; EFFECTIVE IN SUBJECTS WITH INTERFERON INSUSCEPTIBILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-07-16 | — | — | US | disclosed |
| US-6369097-B1 | Treatment and prevention of hepatic disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-09 | — | — | US | disclosed |
| US-6348493-B1 | TREATMENT OF HEPATITIS C BY ADMINISTERING 2,6-DI-TER-BUTYLPHENOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-02-19 | — | — | US | disclosed |
| US-6218437-B1 | ADMINISTERING A THERAPEUTIC AMOUNT OF DI-TERT-BUTYLPHENOL DERIVATIVE TO SUBJECT UNDER CONDITIONS SUCH THAT SAID SYMPTOMS ARE DIMINISHED | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-04-17 | — | — | US | disclosed |
| US-5124347-A | Inhibits 5-lipoxygenase and cyclooxygenase; for treatment of allergies, arthritis, pain | WARNER-LAMBERT CO. (US) | 1992-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | ERBB2 4314/4885EGFR 4415/4885IGF1R 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.